• State Key Lab of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong 510060, China;
Ding Xiaoyan, Email: dingxiaoyan@gzzoc.com
Export PDF Favorites Scan Get Citation

Myopic choroidal neovascularization (MCNV) is one of the main reasons of vision loss in working population in Asia, which has brought economical and social-psychological burdens with high incidence in China, The precise pathogenesis of MCNV is unclear. Metamorphosia is the main reported symptom in these patients. The lesions were usually with smaller area, less leakage and relatively slow progression. Currently, intravitreal anti-vascular endothelial growth factor agents are now the established standard of care for MCNV, which was a major breakthrough in the treatment of MCNV achieving visual acuity improvement. Since the natural history, clinical features and therapy response of this disease is significant different from that in choroidal neovascularization secondary to age-related macular degeneration, the treatment dosing, frequency, retreatment criteria and the follow-up interval should been considerately. Facing the myopia boom in China, there is a need for the development of a precise definition and a more detailed classification for pathogenic myopia, optimize the outcome assessment and follow-up strategy, which should benefit to the further basically and clinical studies.

Citation: Ding Xiaoyan, Chen Chonglin. Understanding the characteristics of myopic choroidal neovascularization to improve its diagnosis and treatment outcome and follow-up strategy. Chinese Journal of Ocular Fundus Diseases, 2017, 33(6): 564-568. doi: 10.3760/cma.j.issn.1005-1015.2017.06.002 Copy

  • Previous Article

    大医精诚 革故鼎新 ——记浙江大学医学院附属第一医院前院长、著名眼底病  专家王竞教授
  • Next Article

    Urgent requirements for clinical translational studies in restoration of injured optic nerve